CN1436195A - 结合整联蛋白的肽衍生物 - Google Patents
结合整联蛋白的肽衍生物 Download PDFInfo
- Publication number
- CN1436195A CN1436195A CN01810941A CN01810941A CN1436195A CN 1436195 A CN1436195 A CN 1436195A CN 01810941 A CN01810941 A CN 01810941A CN 01810941 A CN01810941 A CN 01810941A CN 1436195 A CN1436195 A CN 1436195A
- Authority
- CN
- China
- Prior art keywords
- compound
- amino
- acid residue
- represent
- aforementioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (29)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0009042.3 | 2000-04-12 | ||
GB0009042A GB0009042D0 (en) | 2000-04-12 | 2000-04-12 | Contrast agents |
GB0025070.4 | 2000-10-12 | ||
GB0025070A GB0025070D0 (en) | 2000-10-12 | 2000-10-12 | Contrast agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1436195A true CN1436195A (zh) | 2003-08-13 |
CN1230441C CN1230441C (zh) | 2005-12-07 |
Family
ID=26244091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018109411A Expired - Lifetime CN1230441C (zh) | 2000-04-12 | 2001-04-06 | 结合整联蛋白的肽衍生物 |
Country Status (16)
Country | Link |
---|---|
US (2) | US7351790B2 (zh) |
EP (1) | EP1272507B1 (zh) |
JP (1) | JP5043271B2 (zh) |
KR (2) | KR100879702B1 (zh) |
CN (1) | CN1230441C (zh) |
AT (1) | ATE298763T1 (zh) |
AU (2) | AU5068301A (zh) |
CA (1) | CA2405469C (zh) |
DE (1) | DE60111733T2 (zh) |
DK (1) | DK1272507T3 (zh) |
ES (1) | ES2244607T3 (zh) |
HK (1) | HK1052711A1 (zh) |
NO (1) | NO331741B1 (zh) |
NZ (1) | NZ521735A (zh) |
PT (1) | PT1272507E (zh) |
WO (1) | WO2001077145A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101272808B (zh) * | 2005-01-06 | 2012-03-21 | 通用电气医疗集团股份有限公司 | 光学成像 |
CN108699110A (zh) * | 2015-10-23 | 2018-10-23 | 特温特大学 | 整合素结合肽及其用途 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1230441C (zh) * | 2000-04-12 | 2005-12-07 | 安盛药业有限公司 | 结合整联蛋白的肽衍生物 |
NO20004795D0 (no) * | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
PL207834B1 (pl) | 2001-07-10 | 2011-02-28 | Ge Healthcare As | Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
AU2003226299A1 (en) * | 2002-04-05 | 2003-10-27 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
IL162780A0 (en) * | 2002-04-11 | 2005-11-20 | Kenji Kangawa | Method for producing modified peptide |
GB0224799D0 (en) * | 2002-10-25 | 2002-12-04 | Amersham Plc | Improved complex compositions |
NO20030115D0 (no) * | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
NO20033115D0 (no) * | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
GB0317815D0 (en) * | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
DE602005017475D1 (de) | 2004-03-04 | 2009-12-17 | Ge Healthcare As | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
AU2005254915B2 (en) * | 2004-06-16 | 2011-10-13 | Ge Healthcare As | Peptide-based compounds |
RU2393167C2 (ru) * | 2004-06-16 | 2010-06-27 | Джи-И Хелткер АС | Пептидные соединения |
CA2570963A1 (en) * | 2004-06-18 | 2006-01-26 | David R. Elmaleh | Intravascular imaging device and uses thereof |
ES2358745T3 (es) * | 2004-11-22 | 2011-05-13 | Ge Healthcare As | Agentes de contraste para señalar matriz extracelular. |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
EP2056886A2 (en) * | 2006-08-28 | 2009-05-13 | GE Healthcare Limited | 68ga-labeled peptide-based radiopharmaceuticals |
US20100322857A1 (en) * | 2006-12-11 | 2010-12-23 | Torgrim Engell | Radiolabelled peptide based compounds and uses thereof |
US20090004119A1 (en) * | 2007-06-27 | 2009-01-01 | Ge Healthcare As | Polymers |
DE102007036570A1 (de) * | 2007-08-03 | 2009-02-19 | Siemens Ag | Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests |
US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
AU2018321825A1 (en) * | 2017-08-19 | 2020-03-05 | Ohio State Innovation Foundation | Novel peptide-based cancer imaging agents |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
EP3970801A4 (en) * | 2019-05-14 | 2022-11-02 | Ichimaru Pharcos Co., Ltd. | RAS INHIBITOR PEPTIDE |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US5198208A (en) | 1987-07-16 | 1993-03-30 | Nycomed Imaging As | Aminopolycarboxylic acids and derivatives thereof |
US5753627A (en) * | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
IE901736L (en) | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
UA43823C2 (uk) | 1992-07-06 | 2002-01-15 | Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН |
US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
ZA952485B (en) | 1994-03-28 | 1995-12-15 | Nycomed Imaging As | Liposomes |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
GB9420390D0 (en) | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
JP4903921B2 (ja) | 1995-08-14 | 2012-03-28 | ザ スクリプス リサーチ インスティチュート | αVβ5仲介血管形成の阻止に有効な方法及び組成物 |
WO1997010507A1 (en) | 1995-09-11 | 1997-03-20 | La Jolla Cancer Research Foundation | Molecules that home to a selected organ or tissue in vivo and methods of identifying same |
AU716667B2 (en) | 1996-01-10 | 2000-03-02 | Nycomed Imaging As | Contrast media |
WO1997028830A1 (de) | 1996-02-09 | 1997-08-14 | Steinel Gmbh & Co. Kg | Vorrichtung zum verdunsten eines flüssigen wirkstoffes |
WO1998010795A2 (en) | 1996-09-10 | 1998-03-19 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
HUP0002070A2 (hu) | 1997-05-28 | 2000-10-28 | Genvec, Inc. | Alternatív módon célba juttatott adenovírus |
GB9711115D0 (en) | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
EP1053013A4 (en) | 1998-02-06 | 2004-12-22 | Uab Research Foundation | ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON |
AU2662999A (en) | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
CN1230441C (zh) * | 2000-04-12 | 2005-12-07 | 安盛药业有限公司 | 结合整联蛋白的肽衍生物 |
NO20033115D0 (no) * | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
-
2001
- 2001-04-06 CN CNB018109411A patent/CN1230441C/zh not_active Expired - Lifetime
- 2001-04-06 ES ES01924011T patent/ES2244607T3/es not_active Expired - Lifetime
- 2001-04-06 AU AU5068301A patent/AU5068301A/xx active Pending
- 2001-04-06 PT PT01924011T patent/PT1272507E/pt unknown
- 2001-04-06 AU AU2001250683A patent/AU2001250683B2/en not_active Ceased
- 2001-04-06 NZ NZ52173501A patent/NZ521735A/xx not_active IP Right Cessation
- 2001-04-06 DE DE60111733T patent/DE60111733T2/de not_active Expired - Lifetime
- 2001-04-06 KR KR1020087007515A patent/KR100879702B1/ko not_active IP Right Cessation
- 2001-04-06 WO PCT/NO2001/000146 patent/WO2001077145A2/en active IP Right Grant
- 2001-04-06 DK DK01924011T patent/DK1272507T3/da active
- 2001-04-06 KR KR1020027013674A patent/KR100866666B1/ko not_active IP Right Cessation
- 2001-04-06 EP EP01924011A patent/EP1272507B1/en not_active Expired - Lifetime
- 2001-04-06 AT AT01924011T patent/ATE298763T1/de active
- 2001-04-06 CA CA2405469A patent/CA2405469C/en not_active Expired - Fee Related
- 2001-04-06 JP JP2001575615A patent/JP5043271B2/ja not_active Expired - Lifetime
-
2002
- 2002-10-11 US US10/269,575 patent/US7351790B2/en not_active Expired - Lifetime
- 2002-10-14 NO NO20024932A patent/NO331741B1/no not_active IP Right Cessation
-
2003
- 2003-06-26 HK HK03104595.8A patent/HK1052711A1/zh unknown
-
2008
- 2008-03-24 US US12/053,829 patent/US8404802B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101272808B (zh) * | 2005-01-06 | 2012-03-21 | 通用电气医疗集团股份有限公司 | 光学成像 |
CN108699110A (zh) * | 2015-10-23 | 2018-10-23 | 特温特大学 | 整合素结合肽及其用途 |
Also Published As
Publication number | Publication date |
---|---|
KR20080036662A (ko) | 2008-04-28 |
DK1272507T3 (da) | 2005-10-03 |
ES2244607T3 (es) | 2005-12-16 |
US7351790B2 (en) | 2008-04-01 |
HK1052711A1 (zh) | 2003-09-26 |
DE60111733D1 (de) | 2005-08-04 |
CN1230441C (zh) | 2005-12-07 |
WO2001077145A2 (en) | 2001-10-18 |
CA2405469C (en) | 2012-03-20 |
AU5068301A (en) | 2001-10-23 |
US8404802B2 (en) | 2013-03-26 |
KR100879702B1 (ko) | 2009-01-21 |
US20030204049A1 (en) | 2003-10-30 |
KR100866666B1 (ko) | 2008-11-04 |
EP1272507B1 (en) | 2005-06-29 |
ATE298763T1 (de) | 2005-07-15 |
PT1272507E (pt) | 2005-11-30 |
DE60111733T2 (de) | 2006-05-18 |
JP5043271B2 (ja) | 2012-10-10 |
NO331741B1 (no) | 2012-03-19 |
US20080187493A1 (en) | 2008-08-07 |
NZ521735A (en) | 2004-12-24 |
CA2405469A1 (en) | 2001-10-18 |
AU2001250683B2 (en) | 2006-06-29 |
WO2001077145A3 (en) | 2002-05-10 |
KR20020087973A (ko) | 2002-11-23 |
EP1272507A2 (en) | 2003-01-08 |
JP2003531835A (ja) | 2003-10-28 |
NO20024932D0 (no) | 2002-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1230441C (zh) | 结合整联蛋白的肽衍生物 | |
CN1462276A (zh) | 肽基化合物 | |
CN1622830A (zh) | 肽基化合物 | |
CN1968963A (zh) | 基于肽的化合物 | |
CN1093424C (zh) | 含单胺、联氨、硫羟基的金属螯合剂 | |
CN1829735A (zh) | 显象剂 | |
CN1382062A (zh) | 通过多位点结合的寻靶多体造影剂 | |
CN1074911A (zh) | 将生物作用的物质结合至生物粒子面膜上的化合物,组合物和方法 | |
CN1295578A (zh) | 用于血管生成性疾病成像的药物 | |
CN101068577A (zh) | 施陶丁格连接在用于显像和治疗的显像和治疗目的试剂盒中的应用 | |
CN1302211A (zh) | 与诊断/治疗剂有关的改进 | |
CN1238700A (zh) | 诊断和/或治疗剂的改进或与其相关的改进 | |
CN101065152A (zh) | 靶向尿激酶纤溶酶原激活物受体的造影剂 | |
CN101537190A (zh) | 肽基化合物 | |
CN113292635B (zh) | 靶向cd47的多肽及其应用 | |
JP2008505049A (ja) | ターゲティング組成物及びその製造方法 | |
JP7221937B2 (ja) | 腫瘍標的化ペプチドバリアント | |
US7371728B2 (en) | Prostate-specific antigen probes for optical imaging | |
CN1158621A (zh) | 用于血管疾病诊断的配位化合物 | |
CN1761489A (zh) | 包含载体、靶向部分和造影剂的医学成像用缀合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GE HEALTHCARE AS Free format text: FORMER NAME OR ADDRESS: ANCHEN PHARMACEUTICALS AS |
|
CP01 | Change in the name or title of a patent holder |
Address after: Oslo Patentee after: GE Healthcare AS Address before: Oslo Patentee before: Anchen Pharmaceuticals AS |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171228 Address after: Buckinghamshire Patentee after: GE Healthcare Ltd. Address before: Oslo Patentee before: GE Healthcare AS |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051207 |